Antimetabolite agent combinations in the treatment of cancer

Abstract

A method treating cancer in a subject comprises administering to the subject a therapeutically effective amount of an antimetabolite agent that induces formation of AP sites in cancer cells of the subjects and an amount AP endonuclease inhibitor effective to potentiate the cytotoxicity of the antimetabolite agent to the cancer cells.

Having described the invention, the following is claimed: 
     
         1 . A method of treating cancer in a subject comprising:
 administering to the subject a therapeutically effective amount of an antimetabolite agent that induces formation of AP sites in cancer cells of the subjects and an amount AP endonuclease inhibitor effective to potentiate the cytotoxicity of the antimetabolite agent to the cancer cells.   
     
     
         2 . The method of  claim 1 , the AP endonuclease inhibitor is selected from group consisting of methoxyamine, O-benzylohydroxylamine; ethyl aminooxyacetate; aminooxyacetic acid; ethyl aminooxyacetate; H 2 NOCHMeCO 2 H; carboxymethoxyamine; aminooxyacetic acid; HN═C(NH 2 )SCH 2 CH 2 ONH 2 ; H 2 NO(CH 2 ) 3 SC(NH 2 )═NH; MeOC(O)CH(NH 2 )CH 2 ONH 2 ; H 2 NOCH 2 CH(NH 2 )CO 2 H; canaline; H 2 NO(CH 2 ) 4 ONH 2 ; O-(p-nitrobenzyl)hydroxylamine; 2-amino-4-(aminooxymethyl)thiazole; 4-(aminooxymethyl)thiazole; O,O′-(o-phenylenedimethylene)dihydroxylamine; 2,4-dinitrophenoxyamine; O,O′-(m-phenylenedimethylene)dihydroxylamine; O,O′-(p-phenylenedimethylene)dihydroxylamine; H 2 C═CHCH 2 ONH 2 ; H 2 NO(CH 2 ) 4 ONH 2 ; H 3 C—(CH 2 ) 15 —O—NH 2 , 2,2′-(1,2-ethanediyl)bis(3-aminooxy)butenedioic acid dimethyl diethyl ester; 
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         a compound having a structure of Formula I: 
       
       
         
           
           
               
               
           
         
         wherein X is O or NH, 
         Y is O, S, or NH, 
         Z is absent or represents O, S, or NH, and 
         R represents a hydrogen or a hydrocarbon moiety, 
         and pharmaceutically acceptable salts thereof. 
       
     
     
         3 . The method of  claim 1 , the AP endonuclease inhibitor comprising methoxyamine. 
     
     
         4 . The method of  claim 1 , the antimetabolite agent comprising a nucleoside analog. 
     
     
         5 . The method of  claim 4 , the nucleoside analog comprising 5-aza-2′-deoxycytidine. 
     
     
         6 . The method of  claim 1 , further comprising administering an anticancer agent to the subject. 
     
     
         7 . The method of  claim 6 , the anticancer agent comprising an alkylating agent. 
     
     
         8 . The method of  claim 1 , wherein the amount of antimetabolite agent is subtherapeutic when administered in the absence of the AP endonuclease inhibitor. 
     
     
         9 . The method of  claim 1 , wherein the amount of the AP endonuclease inhibitor is an amount sufficient to sensitize the cancer cells without causing undue sensitization of normal cells. 
     
     
         10 . The method of  claim 1 , wherein the subject is selected as having a cancer at least partially resistant to treatment with antimetabolite agent alone, and wherein the AP endonuclease inhibitor is administered in an amount effective to potentiate the activity of the antimetabolite agent and overcome the resistance. 
     
     
         11 . The method of  claim 1 , wherein said cancer is selected from the group consisting of carcinomas, melanomas, sarcomas, lymphomas, leukemias, astrocytomas, gliomas, malignant melanomas, chronic lymphocytic leukemia, lung cancers, colorectal cancers, ovarian cancers, pancreatic cancers, renal cancers, endometrial cancers, gastric cancers, liver cancers, head and neck cancers, and breast cancers. 
     
     
         12 . A method of treating cancer in a subject comprising:
 administering to the subject a therapeutically effective amount of an antimetabolite agent that induces formation of AP sites in cancer cells of the subjects and an amount of methoxyamine effective to potentiate the cytotoxicity of the antimetabolite agent to the cancer cells.   
     
     
         13 . The method of  claim 12 , the antimetabolite agent comprising a nucleoside analog. 
     
     
         14 . The method of  claim 13 , the nucleoside analog comprising 5-aza-2′-deoxycytidine. 
     
     
         15 . The method of  claim 12 , further comprising administering an alkylating agent to the subject. 
     
     
         16 . The method of  claim 12 , wherein the amount of antimetabolite agent is subtherapeutic when administered in the absence of the methoxyamine. 
     
     
         17 . The method of  claim 12 , wherein the amount of the methoxyamine is an amount sufficient to sensitize the cancer cells without causing undue sensitization of normal cells. 
     
     
         18 . The method of  claim 12 , wherein the subject is selected as having a cancer at least partially resistant to treatment with antimetabolite agent alone, and wherein the methoxyamine is administered in an amount effective to potentiate the activity of the antimetabolite agent and overcome the resistance. 
     
     
         19 . The method of  claim 12 , wherein said cancer is selected from the group consisting of carcinomas, melanomas, sarcomas, lymphomas, leukemias, astrocytomas, gliomas, malignant melanomas, chronic lymphocytic leukemia, lung cancers, colorectal cancers, ovarian cancers, pancreatic cancers, renal cancers, endometrial cancers, gastric cancers, liver cancers, head and neck cancers, and breast cancers. 
     
     
         20 . A method of treating cancer in a subject comprising:
 administering to the subject a therapeutically effective amount of an antimetabolite agent and methoxyamine, the antimetabolite agent comprising a nucleoside analog that induces formation of AP sites in cancer cells of the subject and the methoxyamine being administered at an amount effective to potentiate the cytotoxicity of the nucleoside analog to the cancer cells.   
     
     
         21 . The method of  claim 20 , the nucleoside analog comprising 5-aza-2′-deoxycytidine. 
     
     
         22 . The method of  claim 20 , further comprising administering an alkylating agent to the subject. 
     
     
         23 . The method of  claim 20 , wherein the amount of the methoxyamine is an amount sufficient to sensitize the cancer cells without causing undue sensitization of normal cells. 
     
     
         24 . The method of  claim 20 , wherein the subject is selected as having a cancer at least partially resistant to treatment with antimetabolite agent alone, and wherein the methoxyamine is administered in an amount effective to potentiate the activity of the antimetabolite agent and overcome the resistance. 
     
     
         25 . The method of  claim 20 , wherein said cancer is selected from the group consisting of carcinomas, melanomas, sarcomas, lymphomas, leukemias, astrocytomas, gliomas, malignant melanomas, chronic lymphocytic leukemia, lung cancers, colorectal cancers, ovarian cancers, pancreatic cancers, renal cancers, endometrial cancers, gastric cancers, liver cancers, head and neck cancers, and breast cancers.